Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC), a Delaware corporation, with a report date of March 23, 2020. The filing addresses the status of the Company's listing on The Nasdaq Stock Market LLC regarding compliance with the minimum bid price requirement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory listing status rather than financial performance metrics.
Material Changes and Events
- Nasdaq Delisting Notice: The Company previously failed to maintain the required $1.00 minimum bid price for 30 consecutive business days, triggering a delisting notice effective January 7, 2020.
- Appeal Outcome: On March 23, 2020, the Nasdaq Listing Qualifications Panel granted the Company an extension for continued listing.
- New Compliance Deadline: The Company must regain compliance with the Bid Price Rule by June 12, 2020, to avoid delisting of its Common Stock and Preferred Stock.
Outlook, Risks, and Management Commentary
Risk of Delisting: If the Company fails to achieve a closing bid price of at least $1.00 per share for 10 consecutive business days by June 12, 2020, its securities will be subject to delisting from Nasdaq.
Management Action: The Company previously notified Nasdaq of its intent to cure the deficiency via a reverse stock split, though the filing does not confirm if this action has been completed or if it was the basis for the extension.
Investor Verification Checklist
- Verify the current trading price of CYCC common stock to assess proximity to the $1.00 threshold.
- Confirm whether a reverse stock split has been executed or is pending to address the bid price deficiency.
- Monitor the June 12, 2020 deadline for potential delisting proceedings if compliance is not met.
- Review subsequent filings for updates on the Company's financial condition, as this 8-K contains no financial data.